3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
55
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Polycystic Ovary Syndrome
4
Neoplasms
4
Advanced Breast Cancer
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Carcinoma, Intraductal, Noninfiltrating
3
Recurrence
2
Neoplasms by Site
2
Infertility
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sexual Dysfunctions, Psychological
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Interventions
durvalumab
4
Cisplatin
4
pembrolizumab
3
abemaciclib
3
Pemetrexed
3
Fulvestrant
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ribociclib
2
palbociclib
2
Nivolumab
2
Letrozole
2
Gemcitabine
2
Bevacizumab
2
Anastrozole
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
pralsetinib
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Letrozole
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled